

RECEIVED
CENTRAL FAX CENTER
AUG 15 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:)
David H. Gelfand et al.) EXAMINER: Sitton, Jehanne Souaya
SERIAL NO.: 10/052,417) ART UNIT: 1634
FILED: January 27, 2005) CONFIRMATION NO: 4095
FOR: THERMOSTABLE DNA POLYMERASES INCORPORATING NUCLEOSIDE TRIPHOSPHATES LABELED WITH FLUORESC EIN FAMILY DYES) Atty Docket No. 18915-US2

Certificate of Mailing Via Facsimile

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PAGES 20

Sir:

Facsimile No. 571-273-8300
Date August 15, 2006

I hereby certify that the attached:

- Response to the Non-Final Action Mailed February 15th, 2006 (14 pages)
- Copy of previously submitted Power of Attorney (5 pages).

are being transmitted via facsimile to Mail Stop non-Fee Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


WINSOME ST ROSE

Roche Molecular Systems
1145 Atlantic Avenue
Alameda, California 94501
Tele: (510) 814-2972
Fax: (510) 814-2973

CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being transmitted via facsimile 571-273-8300 on the date shown below with addressed to: Mail Stop: Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Winsome St. Rose

Date

RECEIVED
CENTRAL FAX CENTER
AUG 15 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

David H. Gelfand et al.

SERIAL NO.: 10/052,417

FILED: January 27, 2005

FOR: THERMOSTABLE DNA POLYMERASES
INCORPORATING NUCLEOSIDE
TRIPHOSPHATES LABELED WITH
FLUORESCIN FAMILY DYES

)

) EXAMINER: Sitton, Jehanne Souaya

) ART UNIT: 1634

) CONFIRMATION NO: 4095

) Atty Docket No. 18915-US2

) Date: August 15, 2006

RESPONSE TO OFFICE ACTION

Mail Stop: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action (hereinafter, Action) mailed February 15, 2006, please amend the above-identified application as indicated herein. In addition, please reconsider the application in light of the amendments and remarks below.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 12 of this paper.